The study hypothesizes that donepezil will have a positive impact on brain blood flow deficits in subjects with memory deficits and/or mild dementia and that improvements in brain blood flow will be accompanied by improvements in memory.
The purpose of this study is to assess the safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization, in patients with mild to moderate Alzheimer's disease. This study is now closed to enrollment, but follow-up is continuing for the current participants.
This is a Phase 3 clinical trial in patients ages 50-89 years with mild to moderate Alzheimer's disease to determine safety and efficacy of bapineuzumab. This study is now closed to enrollment, but follow-up is continuing for the current participants.
The purpose of this study is to evaluate the efficacy and safety of Crenezumab, an amyloid antibody, in patients with mild to moderate Alzheimer's disease.
The purpose of this study is to assess the safety, tolerability, and efficacy of ACC-001, an investigational active immunization, in patients with mild to moderate Alzheimer's disease. ACC-001 is a protein designed to act like a vaccine to stimulate the body to produce antibodies to amyloid protein (the presumed cause of Alzheimer's disease) and help remove amyloid protein from the brain.
The purpose of the study is to evaluate the safety and efficacy of davunetide for the treatment of progressive supranuclear palsy (PSP).
